Financing ·
Faeth Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC to establish an at-the-market…
SNSESensei Biotherapeutics, Inc.
Faeth Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC to establish an at-the-market (ATM) offering of up to $150,000,000 in common stock. Additionally, 24,435,594 shares of Series B Non-Voting Convertible Preferred Stock automatically converted into common stock on June 15, 2026, bringing the total outstanding common stock to 25,778,754 shares. Faeth Therapeutics, Inc. is a biotechnology company focused on metabolic diseases.